The beneficial effects of a direct thrombin inhibitor, dabigatran etexilate, on the development and stability of atherosclerotic lesions in apolipoprotein e-deficient mice

Cardiovascular Drugs and Therapy

Volumn 26, Issue 5, 2012, Pages 367-374

  Kadoglou, Nikolaos P E ^a,b   Moustardas, Petros ^a,b   Katsimpoulas, Michael ^a   Kapelouzou, Alkistis ^a   Kostomitsopoulos, Nikolaos ^a   Schafer, Katrin ^a,c   Kostakis, Alkiviadis ^a   Liapis, Christos D ^a,b  

^a BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Atherosclerosis; Dabigatran exetilate; Matrix metalloproteinases; Plaque stability; Thrombin inhibitors

Indexed keywords

APOLIPOPROTEIN E; COLLAGEN; DABIGATRAN ETEXILATE; ELASTIN; FERRIC CHLORIDE; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PLACEBO; THROMBIN INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; AORTA ARCH; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CAROTID ARTERY THROMBOSIS; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTITHROMBINS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BENZIMIDAZOLES; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, KNOCKOUT; NF-KAPPA B; PYRIDINES; TISSUE INHIBITOR OF METALLOPROTEINASE-1; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84867997746     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-012-6411-3     Document Type: Article

References (33)

1. Ambrose JA, Srikanth S. Vulnerable plaques and patients: Improving prediction of future coronary events. Am J Med. 2010;123:10-6.
2. Kadoglou NP, Kostomitsopoulos N, Kapelouzou A, Moustardas P, Katsimpoulas M, Giagini A, et al. Effects of exercise training on the severity and composition of atherosclerotic plaque in apoEdeficient mice. J Vasc Res. 2011;48:347-56.
3. Jennings LK. Mechanisms of platelet activation: Need for new strategies to protect against platelet-mediated atherothrombosis. Thromb Haemost. 2009;102:248-57.
4. Hamilton JR, Cocks TM. Heterogeneous mechanisms of endotheliumdependent relaxation for thrombin and peptide activators of proteaseactivated receptor-1 in porcine isolated coronary artery. Br J Pharmacol. 2000;130:181-8. (Pubitemid 30248443)
5. Hirano K. The roles of proteinase-activated receptors in the vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol. 2007;27:27-36. (Pubitemid 46370476)
6. Smyth SS, McEver RP, Weyrich AS, Morrell CN, Hoffman MR, Arepally GM, et al. Platelet colloquium participants. Platelet functions beyond hemostasis. J Thromb Haemost. 2009;7:1759-66.
7. Levi M, van der Poll T. Two-way interactions between inflammation and coagulation. Trends Cardiovasc Med. 2005;15:254-9. (Pubitemid 41437908)
8. Tracy R. Thrombin, inflammation, and cardiovascular disease. Chest. 2003;124:49S-57.
9. Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost. 2007;98:155-62. (Pubitemid 47078782)
10. Harenberg J, Marx S, Wehling M, Krejczy M. New anticoagulants - promising and failed developments. Br J Pharmacol. 2012;165:363-72.
11. Hankey GJ, Eikelboom JW. Dabigatran etexilate: A new oral thrombin inhibitor. Circulation. 2011;123:1436-50.
12. Fuster JJ, Castillo AI, Zaragoza C, Ibáñez B, Andrés V. Animal models of atherosclerosis. Prog Mol Biol Transl Sci. 2012;105:1-23.
13. Vicente CP, He L, Tollefsen DM. Accelerated atherogenesis and neointima formation in heparin cofactor II deficient mice. Blood. 2007;110:4261-7. (Pubitemid 351377790)
14. Rotzius P, Thams S, Soehnlein O, Kenne E, Tseng CN, Bjorkstrom NK, et al. Distinct infiltration of neutrophils in lesion shoulders in apoe/mice. Am J Pathol. 2010;177:493-500.
15. Kadoglou NP, Liapis CD. Matrix metalloproteinases: Contribution to pathogenesis, diagnosis, surveillance and treatment of abdominal aortic aneurysms. Curr Med Res Opin. 2004;20:419-32. (Pubitemid 38525149)
16. Pynn M, Schäfer K, Konstantinides S, Halle M. Exercise training reduces neointimal growth and stabilizes vascular lesions developing after injury in apolipoprotein e-deficient mice. Circulation. 2004;109:386-92. (Pubitemid 38133909)
17. Tracqui P, Broisat A, Toczek J, Mesnier N, Ohayon J, Riou L. Mapping elasticity moduli of atherosclerotic plaque in situ via atomic force microscopy. J Struct Biol. 2011;174:115-23.
18. Bea F, Kreuzer J, Preusch M, Schaab S, Isermann B, Rosenfeld ME, et al. Melagatran reduces advanced atherosclerotic lesion size and may promote plaque stability in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2006;26:2787-92.
19. Testa L, Bhindi R, Agostoni P, Abbate A, Zoccai GG, van Gaal WJ. The direct thrombin inhibitor ximelagatran/melagatran: A systematic review on clinical applications and an evidence based assessment of risk benefit profile. Expert Opin Drug Saf. 2007;6:397-406. (Pubitemid 351308168)
20. Ylä-Herttuala S, Bentzon JF, Daemen M, Falk E, Garcia-Garcia HM, Herrmann J, et al. Stabilisation of atherosclerotic plaques. Position paper of the European Society of Cardiology Working Group on atherosclerosis and vascular biology. Thromb Haemost. 2011;106:1-19.
21. Clarke M, Bennett M. The emerging role of vascular smooth muscle cell apoptosis in atherosclerosis and plaque stability. Am J Nephrol. 2006;26:531-5. (Pubitemid 46143874)
22. Olson ES, Whitney MA, Friedman B, Aguilera TA, Crisp JL, Baik FM, et al. In vivo fluorescence imaging of atherosclerotic plaques with activatable cell-penetrating peptides targeting thrombin activity. Integr Biol (Camb). 2012;4:595-605.
23. Pou J, Rebollo A, Piera L, Merlos M, Roglans N, Laguna JC, et al. Tissue factor pathway inhibitor 2 is induced by thrombin in human macrophages. Biochim Biophys Acta. 2011;1813:1254-60.
24. DeGraba TJ. Immunogenetic susceptibility of atherosclerotic stroke: Implications on current and future treatment of vascular inflammation. Stroke. 2004;35:2712-9. (Pubitemid 39458377)
25. Newby AC. Metalloproteinases and vulnerable atherosclerotic plaques. Trends Cardiovasc Med. 2007;17:253-8. (Pubitemid 350087694)
26. Feistritzer C, Wiedermann CJ. Effects of anticoagulant strategies on activation of inflammation and coagulation. Expert Opin Biol Ther. 2007;7:855-70. (Pubitemid 46954432)
27. Kaur J, Woodman RC, Kubes P. P38 MAPK: Critical molecule in thrombin-induced NF-kappa B-dependent leukocyte recruitment. Am J Physiol Heart Circ Physiol. 2003;284:H1095-103. (Pubitemid 36348570)
28. Jennewein C, Paulus P, Zacharowski K. Linking inflammation and coagulation: Novel drug targets to treat organ ischemia. Curr Opin Anaesthesiol. 2011;24:375-80.
29. Graebe M, Pedersen SF, Borgwardt L, Højgaard L, Sillesen H, Kjaer A. Molecular pathology in vulnerable carotid plaques: Correlation with [18]-fluorodeoxyglucosepositron emission tomography (FDG-PET). Eur J Vasc Endovasc Surg. 2009;37:714-21.
30. de Nooijer R, Verkleij CJ, von der Thüsen JH, Jukema JW, van der Wall EE, van Berkel TJ, et al. Lesional overexpression of matrix metalloproteinase-9 promotes intraplaque hemorrhage in advanced lesions but not at earlier stages of atherogenesis. Arterioscler Thromb Vasc Biol. 2006;26:340-6. (Pubitemid 43732197)
31. Kadoglou NP, Daskalopoulou SS, Perrea D, Liapis CD. Matrix metalloproteinases and diabetic vascular complications. Angiology. 2005;56:173-89. (Pubitemid 40404472)
32. Holven KB,Halvorsen B, BjerkeliV, Damås JK, RetterstølK, Mørkrid L, et al. Impaired inhibitory effect of interleukin-10 on the balance between matrix metalloproteinase-9 and its inhibitor in mononuclear cells from hyperhomocysteinemic subjects. Stroke. 2006;37:1731-6.
33. Skjøt-Arkil H, Barascuk N, Register T, Karsdal MA. Macrophagemediatedproteolytic remodeling of the extracellular matrix in atherosclerosis results inneoepitopes: A potential new class of biochemical markers. Assay Drug Dev Technol. 2010;8:542-52.